FTCM
TEVA icon

Fir Tree Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Fir Tree Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,177,812
Closed -$115M – 69
2016
Q4 		$115M Buy
3,177,812
+351,600
+12% +$14M 4.65% 9
2016
Q3 		$130M Buy
2,826,212
+70,439
+3% +$3.68M 5.56% 7
2016
Q2 		$138M Sell
2,755,773
-936,156
-25% -$49.8M 5.67% 8
2016
Q1 		$198M Sell
3,691,929
-576,365
-14% -$33.8M 7.48% 4
2015
Q4 		$280M Sell
4,268,294
-425,549
-9% -$26.3M 4.97% 6
2015
Q3 		$265M Buy
4,693,843
+3,272,636
+230% +$212M 4.44% 7
2015
Q2 		$84M Buy
1,421,207
+1,171,207
+468% +$72.2M 1.34% 28
2015
Q1 		$15.6M Sell
250,000
-2,971,114
-92% -$173M 0.22% 44
2014
Q4 		$185M Sell
3,221,114
-615,909
-16% -$34.3M 1.93% 23
2014
Q3 		$206M Buy
3,837,023
+1,191,300
+45% +$63.1M 2.31% 18
2014
Q2 		$139M Sell
2,645,723
-4,413
-0.2% -$226K 1.5% 25
2014
Q1 		$140M Sell
2,650,136
-500,000
-16% -$23.1M 1.57% 25
2013
Q4 		$126M Buy
+3,150,136
New +$124M 1.44% 28

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Fir Tree Capital Management's TEVA Position: Q1 2017 in Review

Fir Tree Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 3,177,812 shares — an estimated $115M sold.

Fir Tree Capital Management first reported a position in TEVA in Q4 2013 and held it in 13 quarters. The position peaked at $280M in Q4 2015. 687 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

  • Fir Tree Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Fir Tree Capital Management sold 3,177,812 Teva Pharmaceuticals shares in Q1 2017, an estimated $115M.
  • Fir Tree Capital Management first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 13 quarters.
  • Fir Tree Capital Management's Teva Pharmaceuticals position peaked at $280M in Q4 2015.
  • 687 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Fir Tree Capital Management's 13F filing for Q1 2017, filed 15 May 2017.